The global biosimilar market is projected to grow at a CAGR of 30%-32% during 2020-2025. The growth of biosimilar market is driven by increasing prevalence of chronic diseases, rising demand for biosimilar drugs, and increase in sedentary lifestyle.
Some of the Key Questions answered in this exclusive report are:
Q.1 What are some of the most promising, high-growth opportunities for the biosimilar market by product (insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, teriparatide, and enoxaparin sodium), technology (recombinant DNA technology and monoclonal antibodies technology), application (oncology, chronic diseases, blood disorders, and autoimmune diseases), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 What are the business risks and threats to the biosimilar market?
Q.4 What are some changing demands of customers in the biosimilar market?
Q.5 What are the new developments in the biosimilar market? Which companies are leading these developments?
Q.6 What strategic initiatives are being implemented by key players for business growth?
Q.7 What are some of the competitive products and processes in this biosimilar area and how big of a threat do they pose for loss of market share via product substitution?
Q.8 What M&A activity has occurred in the last 5 years in this biosimilar market?
Download Brochure of this report by clicking on https://www.lucintel.com/biosimilar-market.aspx
Market Segmentation:
Based on product, the biosimilar market is segmented into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, teriparatide, and enoxaparin sodium. The monoclonal antibodies segment accounted for the largest share of the market in 2020 due to increasing prevalence of chronic diseases, such as cancer, and a rising number of new product developments in the segment.
Europe is expected to be the largest region over the forecast period due to increasing geriatric population, presence of a well-defined regulatory framework by governments for biosimilar, and increasing prevalence of chronic diseases in the region.
Key Players in the biosimilar market are Pfizer, Novartis, Biocon, Fresenius Kabi, Boehringer Ingelheim, Mylan, Eli Lilly Teva Pharmaceutical, Dr. Reddy's Laboratories, and Amgen.
Request Sample Pages by clicking on
https://www.lucintel.com/biosimilar-market.aspx
The report helps stakeholders understand the pulse of the market and provides them with information on key drivers, restraints, challenges, and opportunities for market growth. It would also help to understand the competitors better and gain more insights to improve their position in the business.
To read more about this market please click on https://www.lucintel.com/biosimilar-market.aspx
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.
Brandon Fitzgerald
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. 972.636.5056
Cell: 303.775.0751
